Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this drug for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg.
This drug should be taken once daily with the evening meal to reduce gastrointestinal adverse reactions caused by metformin.
Patients taking this drug 10/1000 mg extended-release tablets or 25/1000 mg extended-release tablets should take 1 tablet once daily.
Patients taking this drug 5/1000 mg extended-release tablets or 12.5/1000 mg extended-release tablets should take 2 tablets at the same time once daily.
To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually.
To maintain the extended-release properties, this drug should be swallowed whole and not split, crushed, ground, or chewed. This drug may not dissolve completely and may be excreted in the stool.
It is not known whether the material excreted in the stool contains the active ingredients of the drug. If a patient repeatedly reports finding this drug in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions, 5. General Precautions).
⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other drugs such as insulin, the recommended initial total daily dose when taking this drug is empagliflozin 10 mg and the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg.
⦁ Patients switching from combination therapy with empagliflozin and metformin to this drug should receive their current doses of empagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and dosage adjustments made as appropriate.
⦁ When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions, 4. Adverse Reactions and 6. Interactions).
Special Populations
Renal Impairment
Because dose adjustment may be required based on renal function, assessment of renal function is recommended before starting this drug and periodically during treatment.
No dosage adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2].
In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and have no other conditions that may increase the risk of lactic acidosis, this drug may be used with adjustment of the metformin hydrochloride dose as follows:
- Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg.
If creatinine clearance (CrCl) decreases to <45 ml/min or estimated glomerular filtration rate (eGFR) decreases to <45 ml/min/1.73m2, this drug should be discontinued immediately.
Elderly Patients
For patients aged 75 years and older, renal function and the risk of volume depletion should be considered.
Improvement of glycemic control in adults with type 2 diabetes mellitus
Type 2 diabetes with difficult blood glucose control
cardiovascular disease
View approved original textHide original text
This medication is used in conjunction with dietary modifications and exercise to improve blood glucose control in adults with type 2 diabetes mellitus. It is especially suitable for patients whose blood glucose levels are not sufficiently controlled and should be used with caution in those with cardiovascular disease. The medication is designed to effectively assist in blood glucose management while ensuring safety in consideration of cardiovascular risks.
How to take
Adult dose
The dose of this drug for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg.
This drug should be taken once daily with the evening meal to reduce gastrointestinal adverse reactions caused by metformin.
Patients taking this drug 10/1000 mg extended-release tablets or 25/1000 mg extended-release tablets should take 1 tablet once daily.
Patients taking this drug 5/1000 mg extended-release tablets or 12.5/1000 mg extended-release tablets should take 2 tablets at the same time once daily.
To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually.
To maintain the extended-release properties, this drug should be swallowed whole and not split, crushed, ground, or chewed. This drug may not dissolve completely and may be excreted in the stool.
It is not known whether the material excreted in the stool contains the active ingredients of the drug. If a patient repeatedly reports finding this drug in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions, 5. General Precautions).
⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other drugs such as insulin, the recommended initial total daily dose when taking this drug is empagliflozin 10 mg and the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg.
⦁ Patients switching from combination therapy with empagliflozin and metformin to this drug should receive their current doses of empagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and dosage adjustments made as appropriate.
⦁ When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions, 4. Adverse Reactions and 6. Interactions).
Special Populations
Renal Impairment
Because dose adjustment may be required based on renal function, assessment of renal function is recommended before starting this drug and periodically during treatment.
No dosage adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2].
In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and have no other conditions that may increase the risk of lactic acidosis, this drug may be used with adjustment of the metformin hydrochloride dose as follows:
- Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg.
If creatinine clearance (CrCl) decreases to <45 ml/min or estimated glomerular filtration rate (eGFR) decreases to <45 ml/min/1.73m2, this drug should be discontinued immediately.
Elderly Patients
For patients aged 75 years and older, renal function and the risk of volume depletion should be considered.
Precautions
This medication is used in the treatment of type 2 diabetes and helps control blood glucose levels.
It can cause a rare side effect known as severe lactic acidosis; therefore, it should not be used in patients with renal function impairment or liver function issues.
Additionally, caution is advised if taken with insulin or sulfonylurea agents due to the risk of hypoglycemia.
Patients with moderate to severe renal impairment, acute infections, dehydration, heart failure, type 1 diabetes, acute or chronic metabolic acidosis should not take this medication.
The medication should be temporarily discontinued before and after using iodine contrast agents during tests, and it should only be resumed after confirming normal kidney function.
This medication can cause side effects such as increased urination, urinary tract infections, and genital infections, so patients should consult a doctor immediately if symptoms of infection appear.
Hypoglycemic symptoms can also occur, so patients should eat regularly, and dose adjustments may be needed when used with drugs that carry a high risk of hypoglycemia.
Elderly patients or those with decreased fluid volume should be closely monitored due to the risk of dehydration and hypotension.
Pregnant or potentially pregnant women and nursing mothers are advised against using this medication.
In cases of overdose, serious side effects such as lactic acidosis may occur, requiring immediate medical treatment, including possible dialysis.
This medication should be swallowed whole without crushing or chewing, and the tablet coating may be excreted in feces, which is normal.
If any unusual symptoms or suspected side effects occur during use, patients should immediately consult their healthcare provider.
Side effects
Hypoglycemia
urinary tract infection
genital infection
increased urination
decreased vitamin B12 and deficiency
ketoacidosis
lactic acidosis
decreased fluid volume
nausea
vomiting
Show 133 moreCollapse
diarrhea
abdominal pain
loss of appetite
constipation
abnormal liver function tests
hepatitis
altered taste
itching
rash
urticaria
erythema
angioedema
difficulty urinating
interstitial nephritis
thirst
increased serum lipids
increased serum creatinine
decreased glomerular filtration rate
vaginismus
vulvitis
balanitis
perineal necrosis
weight loss
constipation
gastritis
dry mouth
gastrointestinal disorders
oral discomfort
salivary gland pain
cerebral infarction
headache
sensory loss
postural dizziness
dizziness
weakness
chest discomfort
chest pain
fever
facial swelling
chills
abnormal sensations
edema
pain
pain at the puncture site
increased alanine aminotransferase
increased aspartate aminotransferase
weight gain
abnormal electrocardiogram
decreased hemoglobin
increased hemoglobin
positive Helicobacter test
positive urine red blood cells
urinary stones
hematuria
renal mass
urinary retention
abnormal urine
vulvar pruritus
genital pruritus
dyslipidemia
hyperglycemia
dermoid cyst
seborrheic dermatitis
atopic dermatitis
diabetic foot
nummular eczema
heat rash
sebaceous gland hyperplasia
lumbar spinal stenosis
myalgia
limb pain
musculoskeletal chest pain
arthralgia
cervical stenosis
fibromyalgia
flank pain
fracture pain
muscle weakness
osteoarthritis
osteoporosis
rotator cuff syndrome
astigmatism
cataract
allergic conjunctivitis
blurred vision
corneal erosion
glaucoma
macular fibrosis
eye discomfort
eye congestion
pathological myopia
retinal detachment
retinal crystals
retinal vein occlusion
macular retinal detachment
eyelid swelling
visual impairment
vitreous floaters
vitreous hemorrhage
epistaxis
asthma
exertional dyspnea
wet cough
allergic rhinitis
sputum retention
cough
skin laceration
rib fracture
ligamentous strain syndrome
angina
palpitations
Prinzmetal's angina
coronary artery disease
tachycardia
arteriosclerosis
deep vein thrombosis
diabetic vascular complications
peripheral artery obstructive disease
anxiety
depression
sleep disorders
acute cholecystitis
autoimmune hepatitis
cholelithiasis
hepatitis
otalgia
postural vertigo
vertigo
anemia
lymphadenopathy
hypothyroidism
thyroid mass
unstable angina
Not everyone experiences these, and they can vary from person to person.
Storage
This medication should be stored in a tightly sealed container to protect it from air and moisture. The storage temperature should be maintained at room temperature between 1 and 30 degrees Celsius.
Appearance and packaging
Appearance
Pale pink, oval-shaped, biconvex, extended-release film-coated tablet
Package unit
30 tablets/bottle
Same-ingredient medicines
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.